Carbohydrate Metabolism Practice Questions

Q: Glycogenin primer is glucosylated by:

UDP Glucose. ### Explanation **Concept Overview:** Glycogenesis (glycogen synthesis) cannot start *de novo*. It requires a primer called **Glycogenin**, a self-glucosylating enzyme. Glycogenin acts as a scaffold and an enzyme to initiate the synthesis of a short glycogen chain (about 8 glucose residues) before Glycogen Synthase takes over. **Why Option A is Correct:** The active donor of glucose units in glycogenesis is **UDP-Glucose**. Glycogenin possesses glucosyltransferase activity; it attaches a glucose molecule from UDP-Glucose to the hydroxyl group of a specific **Tyrosine residue (Tyr-194)** on itself. This process is called autoglucosylation. Once a short chain of glucose is formed, Glycogen Synthase extends the chain using more UDP-Glucose. **Why Other Options are Incorrect:** * **B. Glucose 1-phosphate:** This is an intermediate in the pathway, but it lacks the high-energy bond required for the transfer. It must be converted to UDP-Glucose by the enzyme *UDP-Glucose pyrophosphorylase*. * **C & D. UDP Glucose 1-phosphate / 6-phosphate:** These molecules do not exist as standard substrates in the glycogenesis pathway. Glucose must be phosphorylated at the 6th position (G6P), isomerized to the 1st position (G1P), and then activated by UTP to form UDP-Glucose. **High-Yield Clinical Pearls for NEET-PG:** * **The Primer:** Glycogenin is both an enzyme and a protein primer. * **The Linkage:** The first glucose is attached to the **Tyrosine** residue of Glycogenin via an **O-glycosidic bond**. * **Rate-Limiting Step:** While Glycogenin initiates the process, **Glycogen Synthase** is the rate-limiting enzyme of glycogenesis. * **Energy Requirement:** The formation of one UDP-Glucose molecule from Glucose-1-Phosphate consumes one **UTP** (equivalent to one ATP).

Q: The malate shuttle is important in which of the following processes?

Glycolysis and gluconeogenesis. **Explanation:** The **Malate-Aspartate Shuttle** is a crucial biochemical mechanism used to transport reducing equivalents across the inner mitochondrial membrane, which is impermeable to NADH. **Why Option C is Correct:** 1. **Glycolysis:** This process occurs in the cytosol and generates NADH. For ATP production via the Electron Transport Chain (ETC), these electrons must enter the mitochondria. The malate shuttle facilitates this by reducing oxaloacetate to malate (using NADH), which then crosses into the mitochondria to regenerate NADH for the ETC. 2. **Gluconeogenesis:** A key step involves converting pyruvate to phosphoenolpyruvate (PEP). Pyruvate enters the mitochondria and is converted to oxaloacetate (OAA). However, OAA cannot cross back into the cytosol. It is reduced to malate, transported out via the shuttle, and then re-oxidized to OAA in the cytosol to continue gluconeogenesis. **Why other options are incorrect:** * **Option A:** While essential for aerobic glycolysis, the shuttle is equally vital for gluconeogenesis (transporting OAA equivalents). * **Options B & D:** Glycogen synthesis and glycogenolysis are primarily cytosolic processes involving the phosphorylation and dephosphorylation of glucose molecules; they do not directly depend on the mitochondrial transport of NADH or OAA via the malate shuttle. **High-Yield Clinical Pearls for NEET-PG:** * **ATP Yield:** The Malate-Aspartate Shuttle is more efficient than the Glycerol-3-Phosphate shuttle, yielding **2.5 ATP** per NADH (vs. 1.5 ATP). * **Tissue Specificity:** It is predominantly found in the **heart, liver, and kidneys**. * **Key Enzymes:** It requires Malate Dehydrogenase and Aspartate Aminotransferase (which requires **Vitamin B6**).

Q: Which of the following carbohydrates is most lipogenic?

Fructose. **Explanation:** **Fructose** is the most lipogenic carbohydrate because it bypasses the major rate-limiting step of glycolysis. In the liver, glucose metabolism is strictly regulated by the enzyme **Phosphofructokinase-1 (PFK-1)**. However, fructose enters the glycolytic pathway distal to this step via the action of fructokinase, which converts it to fructose-1-phosphate, eventually forming dihydroxyacetone phosphate (DHAP) and glyceraldehyde-3-phosphate. By bypassing PFK-1, fructose provides an unregulated flow of carbon precursors (Acetyl-CoA and Glycerol-3-phosphate) for **De Novo Lipogenesis (DNL)**. This leads to a rapid increase in fatty acid synthesis and VLDL secretion, often contributing to non-alcoholic fatty liver disease (NAFLD). **Analysis of Incorrect Options:** * **B. Glucose:** Its metabolism is tightly controlled by PFK-1 (inhibited by high ATP and Citrate). This "bottleneck" prevents the rapid flooding of the lipogenic pathway. * **C. Galactose:** It is primarily converted to Glucose-1-phosphate and enters the standard glycolytic pathway, thus remaining subject to the same regulatory constraints as glucose. * **D. Ribose:** This is a pentose sugar primarily utilized in the Pentose Phosphate Pathway (PPP) for nucleotide synthesis rather than being a primary substrate for energy or fat storage. **NEET-PG High-Yield Pearls:** * **Key Enzyme:** Fructokinase has a much higher $V_{max}$ than glucokinase, leading to rapid fructose metabolism. * **Clinical Link:** High dietary fructose is a major driver of hypertriglyceridemia and insulin resistance. * **Essential Fructosuria:** Caused by a deficiency of Fructokinase (asymptomatic). * **Hereditary Fructose Intolerance (HFI):** Caused by a deficiency of Aldolase B (severe; presents with hypoglycemia and jaundice after weaning).

Q: Blood samples for glucose estimation are collected in fluoride bulbs/tubes as fluoride prevents glycolysis by inhibition of which enzyme?

Enolase. **Explanation:** The correct answer is **Enolase (Option A)**. **1. Why Enolase is the correct answer:** In clinical practice, blood glucose estimation requires the prevention of *in vitro* glycolysis by red blood cells (RBCs), which can otherwise decrease glucose levels by approximately 5–10 mg/dL per hour. Sodium fluoride (NaF) is added to the collection tubes (grey-top bulbs) to act as a glycolytic inhibitor. * **Mechanism:** Fluoride ions ($F^-$) bind with magnesium ($Mg^{2+}$) and phosphate to form a **magnesium-fluorophosphate complex**. This complex competitively inhibits **Enolase**, the enzyme responsible for the dehydration of 2-phosphoglycerate to phosphoenolpyruvate (PEP). Since Enolase requires $Mg^{2+}$ as a cofactor, its removal halts the glycolytic pathway. **2. Why other options are incorrect:** * **Aldolase (B):** Cleaves Fructose-1,6-bisphosphate into DHAP and Glyceraldehyde-3-phosphate. It is not inhibited by fluoride. * **Glucokinase (C):** The first step of glycolysis in the liver. While it regulates glucose entry, it is not the target of fluoride. * **Phosphofructokinase (D):** The rate-limiting enzyme of glycolysis, inhibited by high ATP and citrate, but not by fluoride. **3. Clinical Pearls for NEET-PG:** * **The "Grey Top" Tube:** Contains Sodium Fluoride (antiglycolytic agent) and Potassium Oxalate (anticoagulant). * **Delayed Effect:** Fluoride inhibition of Enolase takes about 1–2 hours to fully stabilize glucose levels; therefore, immediate processing is still ideal. * **Fluoride & Urease:** Fluoride also inhibits the enzyme **Urease**. Therefore, fluoride bulbs should **not** be used for blood urea estimation if the laboratory uses the urease method. * **Enolase Isoforms:** Neuron-specific enolase (NSE) is a high-yield clinical marker for small cell lung cancer and neuroblastoma.

Q: A 5-year-old boy presents with hepatomegaly, hypoglycemia, and ketosis. What is the most likely diagnosis?

Glycogen storage disorder. ### Explanation The clinical triad of **hepatomegaly, fasting hypoglycemia, and ketosis** is a classic presentation of **Glycogen Storage Disorders (GSDs)**, specifically those affecting the liver (e.g., Type I - Von Gierke, Type III - Cori, or Type VI - Hers disease). **1. Why Glycogen Storage Disorder is correct:** In GSDs, the body cannot effectively mobilize glucose from stored glycogen during fasting. This leads to: * **Hypoglycemia:** Inability to maintain blood glucose levels. * **Hepatomegaly:** Excessive accumulation of glycogen (or abnormal dextrin) in the liver. * **Ketosis:** To compensate for the lack of glucose, the body shifts to fatty acid oxidation, producing ketone bodies as an alternative fuel source. **2. Why other options are incorrect:** * **A. Mucopolysaccharidosis:** These are lysosomal storage diseases characterized by skeletal deformities (dysostosis multiplex), coarse facial features, and organomegaly, but they do **not** typically cause hypoglycemia or ketosis. * **C. Lipopolysaccharidosis:** This is not a standard clinical diagnosis; it likely refers to sphingolipidoses or disorders of lipid metabolism, which usually present with neurodegeneration or splenomegaly rather than acute fasting hypoglycemia. * **D. Diabetes mellitus:** While DM involves glucose dysregulation, it presents with **hyperglycemia** and polyuria, not hepatomegaly and hypoglycemia. **Clinical Pearls for NEET-PG:** * **Von Gierke (Type I):** Most severe; presents with **lactic acidosis** and hyperuricemia (distinguishes it from Type III). * **Cori Disease (Type III):** Presents with ketotic hypoglycemia and hepatomegaly, but **normal lactate** levels. * **Pompe Disease (Type II):** "Pompe trashes the Pump"; characterized by cardiomegaly and heart failure without significant hypoglycemia. * **McArdle Disease (Type V):** Affects muscle; presents with exercise-induced cramps and myoglobinuria, no hypoglycemia.

Q: In the well-fed state, gluconeogenesis in the liver is inhibited by which of the following?

ADP level. ### Explanation **Correct Option: C. ADP level** Gluconeogenesis is an energy-intensive process requiring 6 ATP equivalents per molecule of glucose synthesized. In the **well-fed state**, the liver has a high energy charge (high ATP, low ADP). Conversely, gluconeogenesis is inhibited when energy levels are low. The key regulatory enzyme **Pyruvate Carboxylase** (which converts pyruvate to oxaloacetate) is **allosterically inhibited by ADP**. High levels of ADP signal a low-energy state, prompting the cell to prioritize ATP production via the TCA cycle rather than consuming energy for glucose synthesis. Additionally, ADP inhibits Phosphoenolpyruvate carboxykinase (PEPCK). **Analysis of Incorrect Options:** * **A & B. Protein breakdown and Alanine:** These occur during **fasting or starvation**. Muscle proteolysis releases amino acids like Alanine, which are transported to the liver to serve as the primary substrates for gluconeogenesis (Glucose-Alanine Cycle). These *stimulate* rather than inhibit the process. * **D. cGMP:** This second messenger is primarily associated with nitric oxide signaling and smooth muscle relaxation. It does not play a direct regulatory role in the hepatic gluconeogenic pathway. **High-Yield NEET-PG Pearls:** * **Most Potent Inhibitor:** **Fructose-2,6-bisphosphate** is the most potent allosteric inhibitor of Fructose-1,6-bisphosphatase (the rate-limiting step of gluconeogenesis). * **Obligatory Activator:** **Acetyl-CoA** is an absolute requirement for Pyruvate Carboxylase activity. High Acetyl-CoA (from fatty acid oxidation) signals the liver to shift from glycolysis to gluconeogenesis. * **Hormonal Control:** Insulin inhibits gluconeogenesis by repressing the synthesis of key enzymes (PEPCK, Glucose-6-Phosphatase), while Glucagon stimulates it via cAMP.

Q: Insulin facilitates glucose uptake in all of the following tissues except:

Heart. **Explanation:** The uptake of glucose into cells is mediated by **Glucose Transporters (GLUT)**. The core concept tested here is the distinction between **insulin-dependent** and **insulin-independent** glucose uptake. **Why the Correct Answer is Heart:** Insulin facilitates glucose uptake primarily in tissues expressing **GLUT-4**, which is the only insulin-responsive transporter. GLUT-4 is found in **Skeletal muscle, Cardiac muscle (Heart), and Adipose tissue**. In these tissues, insulin triggers the translocation of GLUT-4 from intracellular vesicles to the plasma membrane. Therefore, the heart *does* require insulin for facilitated glucose uptake. *(Note: There appears to be a discrepancy in the provided key; scientifically, the Heart is insulin-dependent. If the question asks for tissues where insulin does NOT facilitate uptake, the answer should be Liver, RBC, or Kidney.)* **Analysis of Other Options (Insulin-Independent Tissues):** * **RBCs (GLUT-1):** Rely on constant glucose supply; uptake is insulin-independent. * **Liver (GLUT-2):** While insulin affects hepatic *metabolism* (glycogenesis), the actual *uptake* of glucose via GLUT-2 is insulin-independent and concentration-dependent. * **Kidney (GLUT-2):** Glucose uptake in renal tubular cells is insulin-independent. **High-Yield NEET-PG Pearls:** * **GLUT-1:** Blood-Brain Barrier, RBCs (Basal uptake). * **GLUT-2:** Liver, Pancreatic beta cells, Kidney (High capacity, low affinity). * **GLUT-3:** Neurons (Highest affinity). * **GLUT-4:** Skeletal muscle, Heart, Adipose tissue (**Only one regulated by Insulin**). * **GLUT-5:** Primary transporter for **Fructose** (Small intestine). * **SGLT-1/2:** Active transport (Sodium-dependent) found in the small intestine and kidney tubules.

Q: What is the rate-limiting enzyme in gluconeogenesis?

Fructose-1,6-bisphosphatase. **Explanation** Gluconeogenesis is the metabolic pathway that results in the generation of glucose from non-carbohydrate substrates. It is essentially the reversal of glycolysis, but it must bypass three irreversible steps of glycolysis using four specific enzymes. **Why Fructose-1,6-bisphosphatase is correct:** The conversion of **Fructose-1,6-bisphosphate to Fructose-6-phosphate** by the enzyme **Fructose-1,6-bisphosphatase** is the most important regulatory step and the **rate-limiting step** of gluconeogenesis. This enzyme is allosterically inhibited by Fructose-2,6-bisphosphate and AMP, and stimulated by Citrate. **Why the other options are incorrect:** * **Glucokinase:** This is a glycolytic enzyme found in the liver that converts Glucose to Glucose-6-phosphate. It is involved in glucose utilization, not synthesis. * **Glycerol kinase:** This enzyme converts glycerol to glycerol-3-phosphate in the liver. While it provides a substrate for gluconeogenesis, it is not the rate-limiting enzyme of the pathway. * **Pyruvate dehydrogenase (PDH):** This complex converts Pyruvate to Acetyl-CoA. It is a bridge between glycolysis and the TCA cycle. Crucially, PDH is **inhibited** during gluconeogenesis to prevent the breakdown of pyruvate, redirecting it toward glucose synthesis instead. **High-Yield Clinical Pearls for NEET-PG:** * **Four Key Enzymes of Gluconeogenesis:** Pyruvate carboxylase, PEP carboxykinase (PEPCK), Fructose-1,6-bisphosphatase, and Glucose-6-phosphatase. * **Hormonal Control:** Gluconeogenesis is stimulated by **Glucagon** and **Cortisol**, and inhibited by **Insulin**. * **Biotin Requirement:** Pyruvate carboxylase (the first step) requires Biotin (Vitamin B7) as a cofactor. * **Deficiency:** Deficiency of Fructose-1,6-bisphosphatase leads to fasting hypoglycemia and metabolic acidosis (lactic acidosis).

Q: Which substance can be utilized for gluconeogenesis?

Glycerol. **Explanation:** **Gluconeogenesis** is the metabolic pathway that results in the generation of glucose from non-carbohydrate precursors. **Why Glycerol is Correct:** Glycerol is released during the hydrolysis of triacylglycerols (TAGs) in adipose tissue. It is transported to the liver, where it is phosphorylated by **glycerol kinase** to glycerol-3-phosphate and then oxidized to **dihydroxyacetone phosphate (DHAP)**, a direct intermediate of glycolysis/gluconeogenesis. This allows glycerol to enter the gluconeogenic pathway effectively. **Analysis of Incorrect Options:** * **Glycogen (A):** The breakdown of glycogen is called **glycogenolysis**, not gluconeogenesis. Gluconeogenesis specifically refers to the synthesis of glucose from *non-carbohydrate* sources. * **Acetyl CoA (B):** In humans, Acetyl CoA cannot be converted into glucose because the **pyruvate dehydrogenase (PDH) reaction is irreversible**. Furthermore, for every two carbons of Acetyl CoA entering the TCA cycle, two are lost as $CO_2$, resulting in no net gain of carbon for glucose synthesis. * **Leucine (D):** Leucine and Lysine are the only two **purely ketogenic** amino acids. They are metabolized into Acetyl CoA or Acetoacetate and cannot serve as substrates for glucose. **High-Yield NEET-PG Pearls:** * **Major Substrates:** Lactate (Cori Cycle), Glucogenic amino acids (primarily Alanine), and Glycerol. * **Key Enzyme:** Glycerol kinase is present in the liver and kidneys but **absent in adipose tissue**; therefore, adipocytes cannot reuse glycerol. * **Odd-chain Fatty Acids:** While even-chain fatty acids are not gluconeogenic, **odd-chain fatty acids** yield Propionyl CoA, which can enter the TCA cycle as Succinyl CoA and contribute to gluconeogenesis.

Question 1

Glycogenin primer is glucosylated by:

Accepted Answer

UDP Glucose

Answer

Glucose 1-phosphate

Answer

UDP Glucose 1-phosphate

Answer

UDP Glucose 6-phosphate

Question 2

The malate shuttle is important in which of the following processes?

Accepted Answer

Glycolysis and gluconeogenesis

Answer

Glycolysis only

Answer

Glycogenolysis

Answer

Glycogen synthesis

Question 3

Which of the following carbohydrates is most lipogenic?

Accepted Answer

Fructose

Answer

Glucose

Answer

Galactose

Answer

Ribose

Question 4

Blood samples for glucose estimation are collected in fluoride bulbs/tubes as fluoride prevents glycolysis by inhibition of which enzyme?

Accepted Answer

Enolase

Answer

Aldolase

Answer

Glucokinase

Answer

Phosphofructokinase

Question 5

A 5-year-old boy presents with hepatomegaly, hypoglycemia, and ketosis. What is the most likely diagnosis?

Accepted Answer

Glycogen storage disorder

Answer

Mucopolysaccharidosis

Answer

Lipopolysaccharidosis

Answer

Diabetes mellitus

Question 6

In the well-fed state, gluconeogenesis in the liver is inhibited by which of the following?

Accepted Answer

ADP level

Answer

Protein breakdown in muscle

Answer

Alanine content in the liver

Answer

cGMP

Question 7

A newborn vomits after each feeding of milk-based formula and does not gain weight. Biochemical testing reveals a severe deficiency of galactose-1-phosphate uridyltransferase, consistent with homozygosity. If this condition goes untreated, what is the likely outcome for this patient?

Accepted Answer

Death in infancy

Answer

Benign disease except for cataract formation

Answer

Chronic emphysema appearing in early adulthood

Answer

Chronic renal failure appearing in adolescence

Question 8

Insulin facilitates glucose uptake in all of the following tissues except:

Accepted Answer

Heart

Answer

Liver

Answer

RBC

Answer

Kidney

Question 9

What is the rate-limiting enzyme in gluconeogenesis?

Accepted Answer

Fructose-1,6-bisphosphatase

Answer

Glucokinase

Answer

Glycerol kinase

Answer

Pyruvate dehydrogenase complex (PDH)

Question 10

Which substance can be utilized for gluconeogenesis?

Accepted Answer

Glycerol

Answer

Glycogen

Answer

Acetyl CoA

Answer

Leucine

Carbohydrate Metabolism — MCQs

Carbohydrate Metabolism — MCQs

On this page

Practice by Chapter

Want unlimited practice?